Marker Therapeutics, Inc.

Today, MRKR trades at 0.8928 USD.

For broader market analysis, dive into the technicals on the Marker Therapeutics, Inc. stock price chart and read the latest MRKR news:
– MRKR Q3'26 Earnings: EPS estimate is (0.12) USD
– MRKR Q3'26 Earnings: revenue estimate is 2.12M USD
– Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer

Markets don't sleep, here's what's going on with MRKR at the moment:
– MRKR Q3'26 Earnings: EPS estimate is (0.12) USD
– MRKR Q3'26 Earnings: revenue estimate is 2.12M USD
– Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer

See more updates in real-time with our News Flow.

Marker Therapeutics, Inc. is scheduled to release its next earnings report on Mar 24, 2027.

Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release

How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts

MRKR stock is 6.90% volatile and has beta coefficient of 1.78.

What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable

Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like MRKR are typically less volatile than smaller companies

Track every detail on Marker Therapeutics, Inc. stock chart and check out the list of the most volatile stocks — is Marker Therapeutics, Inc. there?

To understand the MRKR stock performance, it's worth checking price changes for various periods to get the full picture:
– 1 day — −0.30%
– 1 week — −13.32%
– 1 month — −13.32%

MRKR all-time low was 0.6706 USD (Mar 31, 2023), and its highest price is 1,080,432.0000 USD (Apr 15, 2003). Find more dynamics in the Stock Heatmap and on the Marker Therapeutics, Inc. stock chart.

Marker Therapeutics, Inc. market capitalization is ‪16.84 M‬, representing the total value of all its outstanding shares (price × shares outstanding).

What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements

What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Marker Therapeutics, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Marker Therapeutics, Inc. stacks up against other companies

The safest way to buy Marker Therapeutics, Inc. stocks is through a reliable broker. Create an account, fund it, and place a buy order.

You can trade MRKR directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart

Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.

As of Nov 9, 2026, the company has 5 employees.

Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements

See our rating of the largest employers to find more opportunities.

Marker Therapeutics, Inc. stock ticker depends on the exchange where it’s listed. On the NASDAQ, its primary exchange, Marker Therapeutics, Inc. stocks trade under the symbol MRKR.

About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners

Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion

Learn how to find your desired assets in our Symbol Search.

MRKR earnings for the last quarter are −0.09 USD per share, whereas the estimation was −0.13 USD, resulting in a 29.13% surprise. The estimated earnings for the next quarter are −0.12 USD per share.

How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one

Follow other essential metrics in Marker Therapeutics, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk

Marker Therapeutics, Inc. revenue for the last quarter amounts to ‪700.00 K‬ USD despite the estimated figure of ‪660.67 K‬ USD. In the next quarter revenue is expected to reach ‪2.12 M‬ USD.

How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous quarters and year-over-year data
– Track trends: One quarter matters less than consistent performance

Follow other essential metrics in Marker Therapeutics, Inc. financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses

Yes, you can track Marker Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.

Use our Earnings Calendar to never miss important releases and spot opportunities early.

MRKR net income for the last quarter is ‪−1.83 M‬ USD, while the quarter before that showed ‪−3.18 M‬ USD of net income which accounts for 42.56% change.

How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result

Follow other essential metrics in Marker Therapeutics, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control

No, Marker Therapeutics, Inc. does not currently pay dividends to its shareholders.

Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.

What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends

MRKR reached its all-time high of 1,080,432.0000 USD on Apr 15, 2003. Its all-time low was 0.6706 USD and was reached on Mar 31, 2023.

Explore the Marker Therapeutics, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.

Marker Therapeutics, Inc. EBITDA is ‪−10.71 M‬ USD, with an EBITDA margin of −350.68%.

EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.

What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures

What to look at next in Marker Therapeutics, Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality